Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07693543 · ClinicalTrials.gov registry record · Phase 2
Nicotinamide Riboside Supplementation in Chronic Kidney Disease
A Phase 2 study, sponsored by University of California, San Diego.
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07693543 is a Phase 2 study that has not yet begun recruiting, run by University of California, San Diego. The registered enrollment target is 30 participants.
The verdict
NCT07693543, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, San Diego.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is testing whether a dietary supplement called nicotinamide riboside, (NR), can be used in adults with moderate chronic kidney disease. NR is a form of vitamin B3 that may help support cellular energy metabolism. The main goal of this study is to see whether it is feasible for people with chronic kidney disease to take NR daily, complete study visits, and follow the study procedures. The study will also explore whether NR chloride affects markers of mitochondrial health, small blood vessel function, and physical function. Participants will be randomly assigned to one of two treatment orders. One group will take NR first and placebo second. The other group will take placebo first and NR second. Placebo looks like NR but does not contain active NR. Each treatment period lasts 12 weeks, with an approximately 2-week washout period between treatments. Neither participants nor the study team will know which treatment participants are taking during each period. Study visits will include blood and urine collection, physical function testing, and noninvasive tests of small blood vessel function. The study will enroll up to 36 adults with moderate chronic kidney disease at the University of California, San Diego.
Interventions
- DIETARY_SUPPLEMENT Nicotinamide Riboside (NR)
- DIETARY_SUPPLEMENT Matched Placebo (Capsules)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07693543
The ClinicalTrials.gov registry entry for NCT07693543 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nicotinamide Riboside (NR) is the first listed.
NCT07693543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07693543 about?
NCT07693543 is a clinical study titled "Nicotinamide Riboside Supplementation in Chronic Kidney Disease". This study is testing whether a dietary supplement called nicotinamide riboside, (NR), can be used in adults with moderate chronic kidney disease. NR is a form of vitamin B3 that may help support cellular energy metabolism. The main goal of this study is to see whether it is feasible for people wit...
What is the current status of trial NCT07693543?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-10-01. Estimated completion is 2028-09-30.
What interventions are being tested in trial NCT07693543?
The interventions under investigation include: Nicotinamide Riboside (NR) (DIETARY_SUPPLEMENT), Matched Placebo (Capsules) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07693543?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.